Company / R&D Expense
Tilray Brands, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$682.0K
FY2025
5-year range
$284.0K / $1.5M
FY2021-FY2025
Trend
+140.1%
vs FY2024
Sector context
#209 of 210
Health Care
What the data says
Among 210 Health Care companies, Tilray Brands, Inc. is in the bottom 0% for r&d expense. R&D Expense returned to growth in FY2025 after 4 years of decline, reaching $682,000.
Based on SEC 10-K filings.
$682,000 in FY2025 with a 5-year CAGR of -18.7%.
Improved from $635,000 to $682,000 over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- -18.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 210This company $682.0K Sector average $644.1M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -18.7%, indicating a declining trend.
- In FY2025, r&d expense increased 140.1% year-over-year.
- Ranks #209 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $682.0K | +140.1% |
| FY2024 | $284.0K | -55.3% |
| FY2023 | $635.0K | -6.9% |
| FY2022 | $682.0K | -55.1% |
| FY2021 | $1.5M | -20.8% |
| FY2020 | $1.9M | +82.1% |
| FY2019 | $1.1M | -82.1% |
| FY2018 | $5.9M | +84.9% |
| FY2017 | $3.2M | +179.1% |
| FY2016 | $1.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026